Part 2 Mapping challenges in the pathway
Section Takeaways • The care pathway for many patients with eczema and psoriasis is fragmented – with barriers across different parts of the system preventing access to care in line with national guidance. • Almost one in ten people with severe eczema attend more than ten primary care appointments before being diagnosed. • According to patient surveys, around a third of patients with severe eczema have to wait four to seven months before being seen in secondary care after referral. • 56% of trusts waited for Clinical Commissioning Group (CCG) approval before using NICE approved treatments. • 98% of skin disease patients report that their condition affects their emotional and psychological wellbeing, yet only 18% have received some form of psychological support. • 67% of people with very active psoriasis surveyed, reporting that their condition affects their working life, while 43% of feel their psoriasis had limited their income and/or future earnings.
Mapping the current state of play
Restrictions in access to support services
Review and follow up
Local restrictions in access to NICE
Primary care management
Secondary care assessment
Access to treatment
Referral delays to
accessing specialist dermatology services
approved treatment services
Delays to initial diagnosis, exacerbated by limited GP training
Patients remain on same
Technology barriers and digital poverty preventing advantages of PIFU being maximised
treatment option, in
contradiction of NICE guidance
Patients offered access to effective treatments in line with NICE guidance
11
FROM NATIONAL GUIDANCE TO LOCAL ACTION
Made with FlippingBook Ebook Creator